Launch fatigue

- By Risk Staff
- 01 Sep 2007

Tweet
Facebook
LinkedIn
Save this article
Send to
Print this page

Have you ever wanted a transparent way to invest in the orthopaedic repair medical device sector? Or how about the autoimmune-inflammation pharmaceutical industry? If your answer to either of these questions is yes, then you're in luck. These are the niche sectors that New York-based financial products firm XShares hopes to target with its HealthShares exchange-traded fund (ETF) series.

The autoimmune-inflammation pharmaceutical ETF began trading on the New York Stock Exchange (NYSE) on March 9

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to print this content. Please contact info@risk.net to find out more.

You are currently unable to copy this content. Please contact info@risk.net to find out more.

You may share this content using our article tools. Printing this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net

You may share this content using our article tools. Copying this content is for the sole use of the Authorised User (named subscriber), as outlined in our terms and conditions - https://www.infopro-insight.com/terms-conditions/insight-subscriptions/

If you would like to purchase additional rights please email info@risk.net